Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Cost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Shares Outstanding (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Shares Outstanding over the past 15 years, most recently at $37.0 million for Q2 2025.

  • For Q2 2025, Shares Outstanding rose 21.15% year-over-year to $37.0 million; the TTM value through May 2025 reached $37.0 million, up 21.15%, while the annual FY2025 figure was $37.0 million, 21.15% up from the prior year.
  • Shares Outstanding for Q2 2025 was $37.0 million at Lifecore Biomedical, Inc. \De\, roughly flat from $37.0 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $37.0 million in Q2 2025 and troughed at $29.3 million in Q1 2021.
  • A 5-year average of $31.2 million and a median of $30.3 million in 2023 define the central range for Shares Outstanding.
  • Biggest five-year swings in Shares Outstanding: increased 0.37% in 2021 and later rose 21.41% in 2024.
  • Year by year, Shares Outstanding stood at $29.5 million in 2021, then increased by 2.77% to $30.3 million in 2022, then grew by 0.53% to $30.5 million in 2023, then grew by 21.41% to $37.0 million in 2024, then increased by 0.12% to $37.0 million in 2025.
  • Business Quant data shows Shares Outstanding for LFCR at $37.0 million in Q2 2025, $37.0 million in Q1 2025, and $37.0 million in Q4 2024.